SU0268 | CAS#2210228-45-6 | OGG1 inhibitor

MedKoo Cat#: 463689 | Name: SU0268

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SU0268 is a potent and selective OGG1 inhibitor. DNA glycosylases involved in the first step of the DNA base excision repair pathway are promising targets in cancer therapy. There is evidence that reduction of their activities may enhance cell killing in malignant tumors.

Chemical Structure

SU0268

CAS#2210228-45-6

Theoretical Analysis

MedKoo Cat#: 463689

Name: SU0268

CAS#: 2210228-45-6

Chemical Formula: C26H25N3O4S

Exact Mass: 475.1566

Molecular Weight: 475.56

Elemental Analysis: C, 65.67; H, 5.30; N, 8.84; O, 13.46; S, 6.74

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,350.00	2 Weeks
500mg	USD 2,350.00	2 Weeks
1g	USD 3,450.00	2 Weeks
2g	USD 5,850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SU0268; SU 0268; SU-0268;

IUPAC/Chemical Name

4'-(N-(1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-7-yl)sulfamoyl)-[1,1'-biphenyl]-3-carboxamide

InChi Key

XGGNCZLDTJOSFV-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H25N3O4S/c27-25(30)21-4-1-3-20(15-21)17-9-12-23(13-10-17)34(32,33)28-22-11-8-18-5-2-14-29(24(18)16-22)26(31)19-6-7-19/h1,3-4,8-13,15-16,19,28H,2,5-7,14H2,(H2,27,30)

SMILES Code

O=C(C1=CC(C2=CC=C(S(=O)(NC3=CC4=C(C=C3)CCCN4C(C5CC5)=O)=O)C=C2)=CC=C1)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SU0268 is an inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1; IC50 = 0.059 µM).

In vitro activity:

SU0268 is a potentially useful tool in studies of the role of OGG1 in multiple disease-related pathways. SU0268 was confirmed to bind OGG1 both in the absence and in the presence of DNA. SU0268 was selective for inhibiting OGG1 over multiple repair enzymes, including other base excision repair enzymes, and displayed no toxicity in two human cell lines at 10 μM. SU0268 inhibited OGG1 in HeLa cells, resulting in an increase in accumulation of 8-OG in DNA. Reference: J Am Chem Soc. 2018 Feb 14;140(6):2105-2114. https://pubmed.ncbi.nlm.nih.gov/29376367/

In vivo activity:

SU0268 has potential as an alternative treatment for controlling severe inflammatory responses to bacterial infection. SU0268 had a favorable effect on bacterial infection in C57BL/6 wild-type mice by suppressing inflammatory responses, particularly promoting type I IFN responses. SU0268 inhibited proinflammatory responses during Pseudomonas aeruginosa infection and induced the release of type I IFN by the mitochondrial DNA-cGAS-STING-IRF3-IFN-β axis, decreasing bacterial loads and halts disease progression. Reference: J Immunol. 2020 Oct 15;205(8):2231-2242. https://pubmed.ncbi.nlm.nih.gov/32929043/

	Solvent	mg/mL	mM
Solubility
	DMF	10.0	21.03
	DMSO	10.0	21.03
	Ethanol	15.0	31.54

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 475.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Tanushi X, Pinna G, Vandamme M, Siberchicot C, D'Augustin O, Di Guilmi AM, Radicella JP, Castaing B, Smith R, Huet S, Leteurtre F, Campalans A. OGG1 competitive inhibitors show important off-target effects by directly inhibiting efflux pumps and disturbing mitotic progression. Front Cell Dev Biol. 2023 Feb 3;11:1124960. doi: 10.3389/fcell.2023.1124960. PMID: 36819096; PMCID: PMC9936318. 2. Tahara YK, Auld D, Ji D, Beharry AA, Kietrys AM, Wilson DL, Jimenez M, King D, Nguyen Z, Kool ET. Potent and Selective Inhibitors of 8-Oxoguanine DNA Glycosylase. J Am Chem Soc. 2018 Feb 14;140(6):2105-2114. doi: 10.1021/jacs.7b09316. Epub 2018 Feb 5. PMID: 29376367; PMCID: PMC5823510. 3. Qin S, Lin P, Wu Q, Pu Q, Zhou C, Wang B, Gao P, Wang Z, Gao A, Overby M, Yang J, Jiang J, Wilson DL, Tahara YK, Kool ET, Xia Z, Wu M. Small-Molecule Inhibitor of 8-Oxoguanine DNA Glycosylase 1 Regulates Inflammatory Responses during Pseudomonas aeruginosa Infection. J Immunol. 2020 Oct 15;205(8):2231-2242. doi: 10.4049/jimmunol.1901533. Epub 2020 Sep 14. PMID: 32929043; PMCID: PMC7541742.

In vitro protocol:

In vivo protocol:

1. Qin S, Lin P, Wu Q, Pu Q, Zhou C, Wang B, Gao P, Wang Z, Gao A, Overby M, Yang J, Jiang J, Wilson DL, Tahara YK, Kool ET, Xia Z, Wu M. Small-Molecule Inhibitor of 8-Oxoguanine DNA Glycosylase 1 Regulates Inflammatory Responses during Pseudomonas aeruginosa Infection. J Immunol. 2020 Oct 15;205(8):2231-2242. doi: 10.4049/jimmunol.1901533. Epub 2020 Sep 14. PMID: 32929043; PMCID: PMC7541742.

1: Tahara YK, Auld D, Ji D, Beharry AA, Kietrys AM, Wilson DL, Jimenez M, King D, Nguyen Z, Kool ET. Potent and Selective Inhibitors of 8-Oxoguanine DNA Glycosylase. J Am Chem Soc. 2018 Feb 14;140(6):2105-2114. doi: 10.1021/jacs.7b09316. Epub 2018 Feb 5. PMID: 29376367; PMCID: PMC5823510. 2: Qin S, Lin P, Wu Q, Pu Q, Zhou C, Wang B, Gao P, Wang Z, Gao A, Overby M, Yang J, Jiang J, Wilson DL, Tahara YK, Kool ET, Xia Z, Wu M. Small-Molecule Inhibitor of 8-Oxoguanine DNA Glycosylase 1 Regulates Inflammatory Responses during Pseudomonas aeruginosa Infection. J Immunol. 2020 Oct 15;205(8):2231-2242. doi: 10.4049/jimmunol.1901533. Epub 2020 Sep 14. PMID: 32929043; PMCID: PMC7541742. 3: Kant M, Tahara YK, Jaruga P, Coskun E, Lloyd RS, Kool ET, Dizdaroglu M. Inhibition by Tetrahydroquinoline Sulfonamide Derivatives of the Activity of Human 8-Oxoguanine DNA Glycosylase (OGG1) for Several Products of Oxidatively induced DNA Base Lesions. ACS Chem Biol. 2021 Jan 15;16(1):45-51. doi: 10.1021/acschembio.0c00877. Epub 2020 Dec 17. PMID: 33331782; PMCID: PMC9199349. 4: Zhang L, Misiara L, Samaranayake GJ, Sharma N, Nguyen DM, Tahara YK, Kool ET, Rai P. OGG1 co-inhibition antagonizes the tumor-inhibitory effects of targeting MTH1. Redox Biol. 2021 Apr;40:101848. doi: 10.1016/j.redox.2020.101848. Epub 2021 Jan 2. PMID: 33450725; PMCID: PMC7810763. 5: Jun YW, Kool ET. Chemical Tools for the Study of DNA Repair. Acc Chem Res. 2022 Dec 6;55(23):3495-3506. doi: 10.1021/acs.accounts.2c00608. Epub 2022 Nov 10. PMID: 36355579; PMCID: PMC11164294. 6: Fan J, Lv X, Yang S, Geng S, Yang J, Zhao Y, Zhang Z, Liu Z, Guan G, Luo J, Zeng Q, Yin H, Niu Q. OGG1 inhibition suppresses African swine fever virus replication. Virol Sin. 2023 Feb;38(1):96-107. doi: 10.1016/j.virs.2022.11.006. Epub 2022 Nov 23. PMID: 36435451; PMCID: PMC10006199. 7: Tanushi X, Pinna G, Vandamme M, Siberchicot C, D'Augustin O, Di Guilmi AM, Radicella JP, Castaing B, Smith R, Huet S, Leteurtre F, Campalans A. OGG1 competitive inhibitors show important off-target effects by directly inhibiting efflux pumps and disturbing mitotic progression. Front Cell Dev Biol. 2023 Feb 3;11:1124960. doi: 10.3389/fcell.2023.1124960. PMID: 36819096; PMCID: PMC9936318. 8: Pan L, Boldogh I. The potential for OGG1 inhibition to be a therapeutic strategy for pulmonary diseases. Expert Opin Ther Targets. 2024 Mar;28(3):117-130. doi: 10.1080/14728222.2024.2317900. Epub 2024 Feb 14. PMID: 38344773; PMCID: PMC11111349.